Cargando…
Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy
LESSONS LEARNED. There is no presenting parameter that predicts the success of neoadjuvant therapy for pancreatic cancer. Despite the images on scans following neoadjuvant therapy, all patients should be evaluated, because inflammation following radiation therapy (RT) may overstate the extent of tum...
Autores principales: | Sherman, William H., Hecht, Elizabeth, Leung, David, Chu, Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AlphaMed Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759824/ https://www.ncbi.nlm.nih.gov/pubmed/29212734 http://dx.doi.org/10.1634/theoncologist.2017-0208 |
Ejemplares similares
-
A Phase II Study with Lead‐In Safety Cohort of 5‐Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2‐Positive Esophagogastric Adenocarcinomas
por: Shepard, Gregg, et al.
Publicado: (2017) -
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma
por: Mehta, Rutika, et al.
Publicado: (2022) -
N064A (Alliance): Phase II Study of Panitumumab, Chemotherapy, and External Beam Radiation in Patients with Locally Advanced Pancreatic Adenocarcinoma
por: Halfdanarson, Thorvardur R, et al.
Publicado: (2022) -
Association of Modified‐FOLFIRINOX‐Regimen‐Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population
por: Li, Xiang, et al.
Publicado: (2018) -
A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second‐Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma
por: Hecht, J. Randolph, et al.
Publicado: (2017)